Background Coronavirus disease 2019 (COVID-19) is an emerging infectious disease that rapidly spreads worldwide and co-infection of COVID-19 and influenza may occur in some cases. We aimed to describe clinical features and outcomes of severe COVID-19 patients with co-infection of influenza virus. Methods Retrospective cohort study was performed and a total of 140 patients with severe COVID-19 were enrolled in designated wards of Sino-French New City Branch of Tongji Hospital between Feb 8th and March 15th in Wuhan city, Hubei province, China. The demographic, clinical features, laboratory indices, treatment and outcomes of these patients were collected. Results Of 140 severe COVID-19 hospitalized patients, including 73 patients (52.14%) with median age 62 years were influenza virus IgM-positive and 67 patients (47.86%) with median age 66 years were influenza virus IgM-negative. 76 (54.4%) of severe COVID-19 patients were males. Chronic comorbidities consisting mainly of hypertension (45.3%), diabetes (15.8%), chronic respiratory disease (7.2%), cardiovascular disease (5.8%), malignancy (4.3%) and chronic kidney disease (2.2%). Clinical features, including fever (≥38 °C), chill, cough, chest pain, dyspnea, diarrhea and fatigue or myalgia were collected. Fatigue or myalgia was less found in COVID-19 patients with IgM-positive (33.3% vs 50/7%, P = 0.0375). Higher proportion of prolonged activated partial thromboplastin time (APTT) > 42 s was observed in COVID-19 patients with influenza virus IgM-negative (43.8% vs 23.6%, P = 0.0127). Severe COVID-19 Patients with influenza virus IgM positive have a higher cumulative survivor rate than that of patients with influenza virus IgM negative (Log-rank P = 0.0308). Considering age is a potential confounding variable, difference in age was adjusted between different influenza virus IgM status groups, the HR was 0.29 (95% CI, 0.081–1.100). Similarly, difference in gender was adjusted as above, the HR was 0.262 (95% CI, 0.072–0.952) in the COX regression model. Conclusions Influenza virus IgM positive may be associated with decreasing in-hospital death. Supplementary Information The online version contains supplementary material available at 10.1186/s12879-021-05975-2.
【저자키워드】 COVID-19, SARS-CoV-2, Influenza virus IgM, 【초록키워드】 Treatment, coronavirus disease, IgM, Coronavirus disease 2019, severe COVID-19, fatigue, Influenza, Comorbidity, Gender, cardiovascular disease, Influenza virus, Chronic kidney disease, Infectious disease, diabetes, outcome, hospitalized patients, cough, diarrhea, virus, hypertension, Clinical features, cohort study, Laboratory, Spread, China, Features, clinical, Regression model, Fever, Dyspnea, Respiratory disease, Wuhan, Patient, Co-infection, Kidney disease, Emerging infectious disease, age, respiratory, clinical feature, COVID-19 patients, COVID-19 patient, chest pain, myalgia, malignancy, chronic, in some, partial thromboplastin time, In-hospital death, Cox regression model, retrospective cohort study, confounding variable, supplementary material, 95% CI, city, median age, aPTT, severe COVID-19 patients, THROMBOPLASTIN, Tongji Hospital, cumulative, log-rank, positive, chill, chronic respiratory disease, branch, survivor, males, Result, enrolled, collected, proportion, was performed, adjusted, activated, less, occur, groups, COX, New, diabete, patients with influenza, severe COVID-19 patient, 【제목키워드】 Infection, outcome, Characteristics, clinical, Wuhan, China, adults hospitalized,